main content start

Pagina inicial 1

Continue Watching

Últimos vídeos

Últimos vídeos

Brightcove Home Latest Listing

Câncer de mama

Câncer de próstata

Câncer de próstata

Brightcove Cards Listing

Mieloma múltiplo

Mieloma múltiplo

Brightcove Cards Listing

Popular em MedEnrich

Popular em MedEnrich

Popular in Sem nome
  • nasopharyngeal carcinoma44m 35s

    Comprehensive Overview of Nasopharyngeal Carcinoma

    Over the last few years treatment of Nasopharyngeal Carcinoma has evolved with minimally invasive surgery, advances in chemotherapy & immunotherapy.
    nasopharyngeal carcinoma immunotherapy
  • Mieloma múltiplo4m 12s

    Key Practice Points -Myeloma Related Renal Impairment

    In patients with renal impairment primary goal is improvement of Renal Function which is associated with improved treatment outcomes. 50% of patients present renal impairment and renal impairment is severe in 15% of patients.
    myeloma renal impairment key practice points
  • Myelodysplastic Syndromes31m 24s

    Improving Diagnosis of MDS -Innovative Solutions

    Modern Web -Based digital tools based on 10 routinely used clinical parameters and Gradient Based Model can help in non-invasive diagnosis of MDS.
    mds diagnosis web based diagnosis her2negative mbc
  • Câncer de próstata11m 27s

    Management of Advanced Prostate Cancer: nmCRPC

    Recent advances in management of nmCRPC.
  • Mieloma múltiplo6m 23s

    Bone Targeted Treatments in Multiple Myeloma 2024-03-VD-EM-MMY-07

    Long-term usage of bisphosphonates should be balanced with the potential of possible side-effects. Watch the detailed video on MedEnrich to learn about use of bone targeted agents, its dosage, frequency, optimal usage and limitations.
    bisphosphonates convenient agent bone lesions side-effects
  • Oncospecials15m 30s

    A Relevância dos Agentes TKI na era das imunoterapias para o tratamento do carcinoma de células Renais

    ONCOPLUS apresenta: vídeo-aula com Dr. Denis Jardim na patologia de carcinoma de células renais.
    oncologia ccr câncer renal tki sunitinibe
  • Oncospecials6m 24s

    2nd Genenration TKIs for 1st line CP-CML -Selecting Right Patients

    Deep Molecular Responses (DMR) in CML can protect from progression.2nd generation TKIs are associated with higher rates of DMR than 1st generation TKIs.
    2nd generation tki deep molecular response elts high risk e14a2 transcripts
  • Mieloma múltiplo3m 12s

    Tips for Optimising Long Term Lenalidomide Maintenance in Multiple Myeloma

    Dr. Joseph Mikhael explains the triad of maintaining the patients on term Lenalidomide maintenance.
    long term maintenance therapy lenalidomide tips
  • Myelodysplastic Syndromes17m 59s

    Genomics of AML -Therapeutic and Prognostic Implications

    ~40% of AML patients have targetable mutations. Younger patients often have FLT3-ITD or FLT3- TKD mutation. Mutations IDH-1 , IDH-2 & t-53 mutations are more common in elderly patients.
    idh 1& 2 mutations flt3-tkd mutations bcl2 inhibtors genomics of aml
  • Mieloma múltiplo7m 42s

    MRD Assesment in Multiple Myeloma -Ready for Prime Time

    Multiple Myeloma is an incurable disease with patients relapsing even after achieving deep responses. Minimal Residual Disease (MRD) represents a relatively new way of evaluating response to treatment.
    minimum residual disease (mrd) mrd negativity multiple myeloma
  • Webinar passado

    Webinar Cards Listing



    Medbytes Cards Listing
    Hola, ¿puedo ayudar?
    Suporte por bate-papoX
    Equipe de suporte
    Hola, ¿cómo puedo ayudarlo hoy?
    Seleccione una de las siguientes opciones.

    Buscar información

    No puedo iniciar sesión o registrarse

    compartilhar comentarios